Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: Reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse

Journal of Pharmacological Sciences

Volumn 95, Issue 1, 2004, Pages 19-26

  Lovric Bencic, Martina ^a   Sikiric, Predrag ^a   Hanzevacki, Jadranka S ^a   Seiwerth, Sven ^a   Rogic, Dunja ^a   Kusec, Vesna ^a   Aralica, Gorana ^a   Konjevoda, Pasko ^a   Batelja, Lovorka ^a   Blagaic, Alenka B ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Amlodipine; Big endothelin 1; Doxorubicine congestive heart failure; Losartan; Pentadecapeptide BPC157

Indexed keywords

ALANINE AMINOTRANSFERASE; AMLODIPINE; ASPARTATE AMINOTRANSFERASE; BIG ENDOTHELIN 1; CREATINE KINASE; CREATINE KINASE MB; DOXORUBICIN; GLYCYLGLUTAMYLPROLYLPROLYLPROLYLGLYCYLLYSYLPROLYLALANYLASPARTYLASPARTYLALAN YLGLYCYLLEUCYLVALINE; GLYCYLGLUTAMYLPROLYLPROLYLPROLYLGLYCYLLYSYLPROLYLALANYLASPARTYLASPARTYLALANYLGLYCYLLEUCYLVALINE; LACTATE DEHYDROGENASE; LOSARTAN; LOSARTAN POTASSIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG ANTAGONISM; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPOTENSION; MALE; NONHUMAN; RAT; TACHYCARDIA; TACHYPNEA;

EID: 3042835937     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.95.19     Document Type: Article

References (73)

1. Cannan CR, Burnett JC, Lerman A. Enhanced coronary vasoconstriction to endothelin B receptor activation in experimental chronic heart failure. Circulation. 1996;93:646-651.
2. Cannan CR, Verghese M, Lerman A. New insight into coronary endothelial dysfunction. Role of endotehlin. J Lab Clin Med. 1998;131:300-305.
3. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732-736.
4. Berger R, Strecker K, Huelsmann M et al. Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period. J Heart Lung Transpl. 2003;22:1037-1045.
5. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure. Circulation. 1997;96:1976-1982.
6. Nakamura M, Saito S, Yoshida H, Arakawa N, Sugawara S, Hiramori K. Effects of chronic subdepressor dose of angiotensin II type 1 receptor antagonist on endothelium-dependent vasodilatation in patients with congestive heart failure. J Cardiovasc Pharmacol. 2002;40:411-419.
7. Pacher R, Bergler-Klein J, Globits S, et al. Plasma big endothelin-1 concentrations in congestive heart failure compared to systemic hypertension. Am J Cardiol. 1993;71:1293-1299.
8. Trochu JN, Bouhour JB, Kaley G, Hintze TH. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res. 2000;87:1108-1117.
9. Vasku A, Spinarova L, Goldbergova M, et al. The double heterozygote of two endothelin-1 gene polymorphisms (G8002 and -3A/-4A) is related to big endothelin levels in chronic heart failure. Exp Mol Pathol. 2002;73:230-233.
10. Yamauchi Y, Kurosaki E, Azuma H. Pathophysiological role of endothelin-1 in the vascular remodeling process. Folia Pharmacol Jpn (Nippon Yakurigaku Zasshi). 2002;120 Suppl 1:79P-91P. (in Japanese)
11. Yoshizumi M, Kagami S, Suzaki Y, et al. Effect of endothelin-1(1-31) on human mesangial cell proliferation. Jpn J Pharmacol. 2000;84:146-155.
12. Lavallee M, Takamura M, Parent R, Thorin E. Crosstalk between endothelin and nitric oxide in the control of vascular tone. Heart Fail Rev. 2001;6:265-276.
13. Ozaki K, Yamamoto T, Ishibashi T, Matsubara T, Nishio M, Aizawa Y. Regulation of endothelial nitric oxide synthase and endothelin-1 expression by fluvastatin in human vascular endothelial cells. Jpn J Pharmacol. 2001;85:147-154.
14. Wagner FD, Buz S, Knosalla C, Hetzer R, Hocher B. Modulation of circulating endothelin-1 and big endothelin by nitric oxide inhalation following left ventricular assist device implantation. Circulation. 2003;108 Suppl 1:278-284.
15. Wittstein IS, Kass DA, Pak PH, Maughan WL, Fetics B, Hare JM. Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;38:429-435.
16. Hulsmann M, Stanek B, Frey B, et al. Exercise test, endothelin and prognosis in heart failure. J Am Coll Cardiol. 1998;32:1695-1700.
17. Pacher R, Stanek B, Hulsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27:633-641.
18. Wexberg P, Pacher R, Rodler S, et al. Intimal hyperplasia and coronary flow reserve after heart transplantation: association with big endothelin-1. J Heart Lung Transpl. 2002;21:1257-1263.
19. Mikus D, Sikiric P, Seiwerth S, et al. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns. 2001;127:817-827.
20. Sikiric P, Seiwerth S, Grabarevic Z, et al. Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. Dig Dis Sci. 1996;41:1518-1526.
21. G-nitro-L-arginine methylester and L-arginine effect on stomach mucosal integrity and blood pressure. Eur J Pharmacol. 1997;332:23-33.
22. Prkacin I, Aralica G, Perovic D, et al. Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats. J Physiol (Paris). 2001;95:295-301.
23. Sebecic B, Nikolic V, Sikiric P, et al. Osteogenic effect of a gastric pentadecapeptide BPC 157, on the healing of segmental bone defect in rabbits. A comparison with bone marrow and autologous cortical bone implantation. Bone. 1999:24:195-202.
24. Sikiric P, Seiwerth S, Grabarevic Z, et al. The beneficial effect of BPC 157, a 15 aminoacid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life Sci. 1994;54:PL63-PL68.
25. Sikiric P, Seiwerth S, Mise S, et al. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. Burns. 2003;29:323-334.
26. Sikiric P, Separovic J, Anic T, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. J Physiol (Paris). 1999;93:479-485.
27. Bosnjak ZJ, Graf BM, Sikiric P, Stowe DF. Protective effects of newly isolated gastric peptide following hypoxic and reoxygenation injury in the isolated guinea pig heart. FASEB J. 1994;8:A12.
28. Separovic J, Sikiric P, Lovric-Bencic M, Seiwerth S, Cikes I. Pentadecapeptide BPC-157 reduces doxorubicine cardiotoxicity in rats. Fund Clin Pharmacol. 1999;13 Suppl 1:231.
29. Grabarevic Z, Tisljar M, D aja P, et al. The influence of nitric oxide and BPC 157 on stress induced gizzard erosions and development of pulmonary hypertension syndrome in chicks. Dig Dis Sci. 1997;42:216.
30. Grabarevic Z, Tisljar M, Artukovic B, et al. The influence of BPC 157 on nitric-oxide agonists and antagonist induced lesions in broiler chicks. J Physiol (Paris). 1997;91:139-150.
31. Aldieri E, Bergandi L, Riganti C, Costamagna C, Bosia A, Ghigo D. Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation. Toxicol Appl Pharmacol. 2002;185:85-90.
32. Jung ID, Lee JS, Yun SY, et al. Doxorubicin inhibits the production of nitric oxide by colorectal cancer cells. Arch Pharm Res. 2002;25:691-696.
33. Konjevoda P, Nasic M, Curkovic T, Sikric P, Seiwerth S, Stambuk N. Effects of BPC 157 on the healing of comeal lesions. In: Ohno S, Aoki K, Usui M, Uchio E, editors. Uveitis today. Amsterdam/Lausanne/New York/Oxford/Shannon/ Singapore/Tokyo: Elsevier; 1998. p. 311-314.
34. Seiwerth S, Sikiric P, Grabarevic Z, et al. BPC 157 effect on healing. J Physiol (Paris). 1997;91:173-178.
35. Zoricic I, Sikiric P, Seiwerth S, et al. Pentadecapeptide BPC 157 beneficially influences the healing of colon-colon anastomosis in rats. In: Mozsik G, Nagy L, Par A, Rainsford KD, editors. Cell injury and protection in the gastrointestinal tract. From basic sciences to clinical perspectives 1996. Dodrecht/Boston /London: Kluwer Academic Publishers; 1997. p. 249-258.
36. Veljaca M, Chan K, Guglietta A. Digestion of h-EGF, h-TGF alpha, and BPC-15 in human gastric juice. Gastroenterology. 1995;108:761.
37. Veljaca M, Krnic Z, Brajsa K, et al. The development of PL 14736 for treatment of inflammatory bowel disease. Proceedings of IUPHAR-GI Section Symposium, Honolulu, Hawaii, July 13-15, 2002; O-32.
38. Aspenberg P, Forslund C. Enhanced tendon healing with GDF 5 and 6. Acta Orthop Scand. 1999;70:51-54.
39. Franklin TJ, Gregory H, Morri SW. Acceleration of wound healing by recombinant human urogastrone (epidermal growth factor). J Lab. 1986;108:103-108.
40. Kreuzer T, Grube R, Zarkovic N, Schaur RJ. 4-Hydroxynonenal modifies the effects of serum growth factors on the expression of the c-fos proto-oncogene and the proliferation of HeLa carcinoma cells. Free Radic Biol Med. 1999;25:42-49.
41. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orth Res. 2003;21:976-983.
42. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation. 1995;91:691-697.
43. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
44. Donmez G, Derici U, Erbas D, et al. The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension. Jpn J Physiol. 2002;52:435-440.
45. Elkayam U. Calcium channel blockers in heart failure. Cardiology. 1998;89 Suppl 1:38-46.
46. Gheorghiade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO. Current medical therapy for advanced heart failure. Am Heart J. 1998;35:S231-S248.
47. Iliceto S. Left ventricular dysfunction: which role for calcium antagonists? Eur Heart J. 1997;18 Suppl A:A87-A91.
48. Kobayashi N, Yanaka H, Tojo A, Kobayashi K, Matsuoka H. Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats. J Cardiovasc Pharmacol. 1999;34:173-181.
49. Martinez Y, Martinez S, Meaney A, Meaney E, Escalante B. Angiotensin II type 1 receptor blockade restores nitric oxide-dependent renalvascular rasponses in renovascular hypertension. J Cardiovasc Pharmacol. 2002;40:381-387.
50. Mital S, Loke KE, Slater JP, Addonizio L, Gersony WM, Hintze TH. Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulationg myocardial oxygen consumption in normal canine and failing human hearts. Am J Cardiol. 1999;83 (17A):92H-98H.
51. Nikolaidis LA, Doverspike A, Huerbin R, Hentosz T, Shannon RP. Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by bradykinin-mediated, nitric oxide-dependent mechanism. Circulation. 2002;105:2785-2790.
52. Pitt B. Evaluation of Losartan in the Elderly (ELITE) Trial: clinical implications. Eur Heart J. 1997;18:1197-1199.
53. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure. (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
54. Wang WZ, Matsumori A, Yamada T, et al. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. Circulation. 1997;95:245-251.
55. Kawasaki N, Lee JD, Shimizu H, Ueda T. Long term 1-camitine treatment prolongs the survival in rats with adriamycin-induced heart failure. J Cardiac Failure. 1996;2:293-299.
56. Ganz WI, Sridhar KS, Ganz SS, Gonzales R, Chakko S, Serafini A. Review of tests for monitoring doxorubicine-induced cardiomyopathy. Oncology. 1996;53:461-470.
57. Loffler BM, Guillarmod HJ, Marie JP. Concentrations and ratios of immunoreactive big-endothelin-1 and endothelin-1 in human, rat and rabbit plasma. Biochem Int. 1992;27:755-761.
58. Lundblad R, Giercksky KE. Endothelin concentrations in experimental sepsis: profiles of big endothelin and endothelin 1-21 in lethal peritonitis in rats. Eur J Surg. 1995;161:9-16.
59. Kaplan MM. Liver dysfunction secondary to congestive heart failure. Practical Cardiol. 1980;6:39.
60. Kubo SH, Walter BA, John DA, Clark M, Cody RJ. Liver function abnormalities in chronic heart failure: influence of systemic hemodynamics. Arch Intern Med. 1987;147:1227.
61. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 1998;97:576-580.
62. Zhang X, Kichuk MR, Mital S, et al. Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts. Am J Cardiol. 1999;84(4A):27L-33L.
63. Zhang X, Recchia FA, Bernstein R, Xu X, Nasjletti A, Hintze TH. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure. J Pharmacol Exp Ther. 1999;288:742-751.
64. Zhang X, Xu X, Nasjletti A, Hintze TH. Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels. J Cardiovasc Pharmacol. 2000;35:195-202.
65. Zarkovic N, Schaur RJ, Puhl H, Jurin M, Esterbauer H. Mutual dependence of growth modifying effects of 4-hydroxy-nonenal and fetal calf serum in vitro. Free Radic Biol Med. 1994;16:877-884.
66. Zarkovic N, Zarkovic K, Schaur RJ, et al. 4-Hydroxynonenal as a second messenger of free radicals and growth modifying factor. Life Sci. 1999;65:1901-1904.
67. Costa LE, La-Padula P, Lores-Arnaiz S, et al. Long-term angiotensin II inhibition increases mitochondrial nitric oxide synthase and not antioxidant enzyme activities in rat heart. J Hypertens. 2002;20:2487-2494.
68. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT 1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 2002;40:521-527.
69. Loke KE, Messina EJ, Shesely EG, Kaley G, Hintze TH. Potential role of eNOS in the therapeutic control of myocardial oxygen consumption by ACE inhibitors and amlodipine. Cardiovasc Res. 2001;49:86-93.
70. Okamura K, Jin D, Takai S, Miyazaki M. Beneficial effects of angiotensin-converting enzyme inhibition in adramycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol. 2002;88:183-188.
71. Mohler ER 3rd, Sorensen LC, Ghali JK, et al. Role of cytokines in the mechanism of action of amlodipine: The PRAISE Heart Failure Trial. J Am Coll Cardiol. 1997;30:35-41.
72. Packer M, O Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107-1114.
73. Pousset F, Isnard R, Lechat P, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J. 1997;18:254-258.